Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literature
© Nozières et al; licensee BioMed Central Ltd. 2011
Received: 27 April 2011
Accepted: 24 October 2011
Published: 24 October 2011
Somatotropinoma, a pituitary adenoma characterised by excessive production of growth hormone (GH), is extremely rare in childhood. A genetic defect is evident in some cases; known genetic changes include: multiple endocrine neoplasia type 1 (MEN1); Carney complex; McCune-Albright syndrome; and, more recently identified, aryl hydrocarbon receptor-interacting protein (AIP). We describe seven children with somatotropinoma with a special focus on the differences between genetic and sporadic forms.
Seven children who presented in our regional network between 1992 and 2008 were included in this retrospective analysis. First-type therapy was somatostatin (SMS) analogues or transsphenoidal surgery. Control was defined as when insulin-like growth factor-1 (IGF-1) levels were within the normal range for the patient's age at 6 months after therapy, associated with decreasing tumour volume.
Patients were aged 5-17 years and the majority (n = 6) were male. Four patients had an identified genetic mutation (McCune-Albright syndrome: n = 1; MEN1: n = 1; AIP: n = 2); the remaining three cases were sporadic. Accelerated growth rate was reported as the first clinical sign in four patients. Five patients presented with macroadenoma; invasion was noted in four of them (sporadic: n = 1; genetic: n = 3). Six patients were treated with SMS analogues; normalisation of IGF-1 occurred in one patient who had a sporadic intrasellar macroadenoma. Multiple types of therapy were necessary in all patients with an identified genetic mutation (4 types: n = 1; 3 types: n = 2; 2 types: n = 1), whereas two of the three patients with sporadic somatotropinoma required only one type of therapy.
This is the first series that analyzes the therapeutic response of somatotropinoma in paediatric patients with identified genetic defects. We found that, in children, genetic somatotropinomas are more invasive than sporadic somatotropinomas. Furthermore, SMS analogues appear to be less effective for treating genetic somatotropinoma than sporadic somatotropinoma.
Somatotropinoma is a pituitary adenoma characterised by excessive production of growth hormone (GH) from the pituitary gland . In adulthood, somatotropinoma is associated with severe symptoms, including organomegaly and dysmorphia , and diagnosis is usually delayed by six years after the initial presentation of symptoms . Somatotropinoma is rare in childhood and adolescence, and there is little literature on this topic. As in adults, diagnosis in children is delayed, but clinical presentation differs with accelerated growth being the first symptom observed after dysmorphic features .
Genetic defects have been recently identified in some somatotropinoma cases. These defects include multiple neoplasia syndromes, including the multiple endocrine neoplasia type 1 (MEN1) [4, 5], the Carney complex  and McCune-Albright syndrome . Recently, mutations in the aryl hydrocarbon receptor interacting protein gene (AIP) were identified in some patients with familial isolated pituitary adenoma (FIPA) [8, 9]. Such mutations account for 15% of FIPA kindreds and are associated with somatotropinomas, prolactinomas, non-secreting adenomas and rare cases of Cushing disease . We present data on all children developing a somatotropinoma before 18 years of age between 1992 and 2008 in our regional network for the management of paediatric patients with endocrine disorders. Four of the children presented with a known genetic defect. The aim of this work was to analyse the clinical, biological, radiological and therapeutic aspects of these adenomas.
All children (n = 7) with a GH-secreting pituitary adenoma that was diagnosed before 18 years of age in three hospitals in France [Lyon (n = 5), Saint-Etienne (n = 1) and Grenoble (n = 1)] were included in this analysis. One case was diagnosed in 1992 (when the patient was six years of age), and the other six cases were diagnosed between 2005 and 2008. We excluded patients with GH-independent gigantism, such as Beckwith-Wiedemann syndrome or Sotos syndrome, and patients with GH-releasing hormone secreting tumours.
A diagnosis of excessive production of GH was established by a high level of serum GH over 24 hours, not suppressible to <1 μg/L, 180 minutes after a 75 g oral glucose tolerance test, or a high insulin-like growth factor-1 (IGF-1) level for the patient's age.
Magnetic resonance imaging (MRI) was performed in six cases; images were analysed by the same radiologists. Invasiveness on MRI was assessed using the Hardy-Vezina classification . Tumours were considered as invasive when presenting with extrasellar expansion to the cavernous or sphenoidal sinus. For the oldest case, computed-tomography scanning was performed in 1992, and monitoring was done by MRI from 2000 onwards.
Serum GH levels were measured by radioimmunometric assay calibrated to the WHO 98/574 standard. Before 1995, the GH assay (for one patient) was performed using a polyclonal antibody kit.
Serum IGF-1 levels were measured using the IGF-1 RIACT kit (CIS Bio International). Results were presented as standard deviation (SD), adjusted for sex, age and pubertal stage. Prolactin was measured by radioimmunometric assay calibrated on 84/500 standard. Other hormones of the pituitary axis were also studied.
Somatostatin (SMS) analogues or transsphenoidal surgery were the first-type treatment, depending on each patient's clinical evolution and criteria. Patients received long-acting octreotide (10-30 mg) or lanreotide (30-120 mg), managed by the patient's clinician, according to IGF-1 level and growth curve. Patients also received cabergoline at a dose of 0.5 mg once to three times weekly.
Control was defined as when IGF-1 was within the normal range for the patient's age at six months after therapy, associated with a decreasing tumour volume of more than 30%. SMS analogue resistance was defined in the present study as an IGF-1 level of more than +2 SD at six months when receiving the maximum dose of octreotide or lanreotide.
Baseline clinical characteristics of patients with somatotropinoma
Date of diagnosis
Age at diagnosis (years)
Symptoms/reason for consultation
Size at diagnosis (SD)
Monitoring of McCune-Albright syndrome
Bone deformity, non-measurable size
Acquired resistance to cabergoline
Therapeutic intervention and follow-up in patients with somatotropinoma
IGF1 (μg/L) and MRI at diagnosis
Control of disease
Last IGF1 (μg/L) and MRI
406 (+3SD) Hyperplasia 565 (+4SD)
Octreotide LAR 30 mg (monthly- 18 months)
+ Cabergoline 1 mg/week
Pegvisomant 20 mg/day
333 (-1SD) NA
Invasive Macroadenoma (36 × 27 × 28 mm) 1259 (+4SD)
Octreotide LAR 30 mg monthly (6 months - growth of adenoma with visual disturbance; 3 surgeries)
+ Cabergoline with visual (1 mg/week)
689 (+2.5SD) 14 × 10 mm (-68%)
Invasive Macroadenoma (21 × 26 mm) 997 (+4SD)
Lanreotide LAR 90 mg monthly (6 months)
Octreotide LAR 30 mg monthly + cabergoline (1 mg/week)
1184 (+4SD) 10 × 12 × 9 mm (-50%)
Invasive Macroadenoma (16 × 21 × 11 mm) 934 (+4SD)
Lanreotide LAR 60 mg monthly (6 months)
451 (0SD) No visible adenoma
Negative genetic analysis (Carney, MEN1, AIP)
Non invasive macroadenoma (19 × 14 × 20 mm)
Lanreotide LAR 60 mg monthly
282 (+1SD) No visible adenoma
Negative genetic analysis (MEN1, AIP)
777 (+3SD) Invasive macroadenoma (26 × 26 × 32 mm)
Octreotide LAR 30 mg monthly (6 months) added to the previous Dopamine agonist treatment (Cabergoline 1,5 mg/week)
717(+3SD) 34 × 21 × 23 mm (+6%)
Negative genetic analysis (Carney, MEN1, AIP)
574 (+4SD) Microadenoma (7,6 × 9 × 7,5 mm)
504 (+1,5 SD) No visible adenoma
At the end of treatment, four patients had normal IGF-1 levels for their age, sex and pubertal stage (Figure 3, Table 2). Normalization of IGF-1 levels occurred in two out of the three patients with a sporadic form (patients 5 and 7) who received only one type of therapy and two out of the four patients with a genetic form who received 2-3 types of therapy. Disease control was not achieved in patients 2 and 3 and 6. A decrease in growth was observed when disease control was achieved (Figure 1).
This series of paediatric patients is one of the largest series of somatotropinomas in children and gives new information on the therapeutic management of this disease. Recent epidemiological data have shown that the overall prevalence of pituitary adenomas was greater than previously estimated. It was measured at 94.4 and 77.6/100,000 inhabitants in the and Belgium  and United Kingdom  respectively, with somatotropinomas representing 13% and 11% of pituitary adenomas [12, 13]. However, epidemiological data remain scarce in children. In accordance with our results, the literature reports a higher prevalence of GH-secreting pituitary adenomas in boys than in girls [14–19]. This may be particularly true for genetic forms, and particularly in patients with AIP-related pituitary adenomas. Daly et al. showed recently in a series of 96 AIP patients that 63.5% of them were male . In contrast, in a series of 83 a priori sporadic somatotropinomas in adults and young patients, Tichomirowa et al.  observed that only 44.5% were male. However, an AIP mutation was identified in eleven cases (13.3%), and eight of them were men.
The presentation of somatotropinoma in children differs according to whether the epiphyseal plate has fused or not. In the former situation, symptoms are similar to those seen in acromegalic adults . In contrast, if somatotropinoma occurs prior to fusion of the epiphyseal plate, accelerated growth ensues with large size and extreme "gigantism" . In our series, four patients had accelerated growth, two of whom had genetic forms of somatotropinoma. Daly et al. showed that in adult patients with AIP-related pituitary adenoma, gigantism was significantly more frequent than in controls (32% vs. 6.5%; p < 0.000001) . In our series, whatever the age at diagnosis, the majority of patients presented with enlarged hands and feet.
Most pituitary adenomas in childhood are macroadenomas, and locally invasive tumours are frequently observed [15, 21]; headaches and visual disturbances are, therefore, common [15, 21, 22]. In our series, five of seven patients presented with macroadenoma; of these patients, four had invasive macroadenomas, and three of these four had a genetic mutation (one MEN1, two AIP). This is consistent with the literature in adult patients, which reports larger tumours and a more aggressive presentation in patients with MEN1 versus without MEN1 (85% vs. 42%; p < 0.001) . Recently, Daly et al. showed that the maximum tumour diameter was higher in patients with AIP-related somatotropinoma adenoma (n = 75) than in age-matched AIP-negative patients (n = 232) (22.5 [7.0-60] vs. 16.0 [3.0-48] mm; p < 0.00026) .
Moreover, four studies reported a high proportion of genetic forms in children and young subjects [20, 23–25]. Three of them [23–25] included, as did our study, seven cases of acromegaly in young subjects, with identification of a genetic form in 2-4 cases. In the fourth study, conducted by Tichomirowa et al., which included 39 patients with a pituitary macroadenoma diagnosed before 18 years, an AIP mutation was identified in 20.5% of cases .
In both adults and children, conventional treatment of somatotropinoma is transsphenoidal surgery [15, 18]. In cases of intracavernous extension, or when surgery has been incomplete, pre- and/or post-operative SMS analogue treatment may be administered [16, 26] and has been shown to be safe in paediatric patients . The GH receptor antagonist pegvisomant, or cabergoline in cases of somato-prolactinomas, can be used in acromegalic patients who have failed to respond to conventional treatment [14, 27]. In our region, SMS analogues were effective in one of the six cases in whom they were used.
Cabergoline was administered to two patients in our series (both with genetic somatotropinoma) as second-type therapy in combination with SMS analogues. One of these patients required no further therapy, while the other (who had McCune-Albright syndrome) was switched to pegvisomant, which successfully reduced IGF-1 levels to -1 SD, consistent with the literature [28, 29].
In adults, genetic forms of somatotropinoma are more difficult to control than sporadic forms. In a study of adult patients with pituitary adenomas, Verges et al. observed a normalization of pituitary hypersecretion in 90% of patients with sporadic adenomas and 42% of patients with MEN1 genetic alterations . To date, little is known on the therapeutic response in children. Personnier et al., in a recent review, observed that GH control was obtained in 69% of cases in children ; in that analysis, genetic and sporadic forms were analyzed together. Accordingly, in another series of eleven sporadic paediatric pituitary adenomas, six were considered to be controlled by SMS analogues before and after surgery. Tumour size was reduced by 51.0% overall . In contrast, Tichomirowa et al.  observed that, in a series of eleven paediatric and young patients with an AIP-related somatotropinoma, at least two surgical interventions were necessary in 36.4% of cases, and that post-operative SMS analogue therapy was only effective in 11% of patients . In our series, control was achieved in two out of the three patients with a sporadic somatotropinoma after one type of therapy. In contrast, all patients with genetic somatotropinoma required two (n = 2) or three (n = 2) types of therapy, and only two out of four such patients were cured. Three patients received SMS analogues as first-type therapy; these were followed by cabergoline, pegvisomant or transsphenoidal surgery. In the fourth patient, transsphenoidal surgery was ineffective as first-type therapy, and IGF-1 levels remained +2 SD even after subsequent SMS analogues and radiotherapy. These findings suggest that SMS analogues have little efficacy in patients with genetic somatotropinoma and that, as reported in adults , hormonal control is more difficult to achieve in patients with genetic somatotropinomas than in patients with sporadic forms.
Somatotropinomas in children and adolescents are rare and more aggressive than those seen in adults. In this small series of patients, genetic somatotropinomas were more invasive than sporadic somatotropinomas. Our data suggest that SMS analogues, while effective in sporadic somatotropinoma, are less effective in genetic somatotropinoma. Further research on the incidence and types of genetic mutations in children and adolescents with somatotropinoma is necessary to increase our understanding of the disease. In addition, studies of different therapeutic options in genetic somatotropinoma would provide more information about why SMS analogues are less effective in these patients, and allow for the development of new treatment strategies in this setting.
This study was supported by Pfizer. Medical writing assistance was provided by Claire Byrne of in Science Communications (a Wolters Kluwer business), and funded by Pfizer. Written consent for publication was obtained from the patients or their relatives.
- Keil MF, Stratakis CA: Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother. 2008, 8: 563-574. 10.1586/14737220.127.116.113.PubMed CentralView ArticlePubMedGoogle Scholar
- Horvath A, Stratakis CA: Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord. 2008, 9: 1-11. 10.1007/s11154-007-9066-9.View ArticlePubMedGoogle Scholar
- Lamberts SW, van der Lely AJ, de Herder WW: Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up. J Clin Endocrinol Metab. 1995, 80: 3111-3113. 10.1210/jc.80.11.3111.PubMedGoogle Scholar
- Vergès B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A: Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002, 87: 457-465. 10.1210/jc.87.2.457.View ArticlePubMedGoogle Scholar
- Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O'Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV: Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM. 1996, 89: 653-669.View ArticlePubMedGoogle Scholar
- Stergiopoulos SG, Abu-Asab MS, Tsokos M, Stratakis CA: Pituitary pathology in Carney complex patients. Pituitary. 2004, 7: 73-82. 10.1007/s11102-005-5348-y.PubMed CentralView ArticlePubMedGoogle Scholar
- Albright F, Butler AM, Hampton AO, Smith P: Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation, and endocrine dysfunction, with precocious puberty in females: report of 5 cases. N Engl J Med. 1937, 216.Google Scholar
- Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TML, Salmela PI, Paschke R, Gündogdu S, De Menis E, Mäkinen MJ, Launonen V, Karhu A, Aaltonen LA: Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006, 312: 1228-1230. 10.1126/science.1126100.View ArticlePubMedGoogle Scholar
- Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wémeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab. 2006, 91: 3316-3323. 10.1210/jc.2005-2671.View ArticlePubMedGoogle Scholar
- Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montañana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Longás AF, Labarta Aizpún JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SPA, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A: Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010, 95: E373-383. 10.1210/jc.2009-2556.View ArticlePubMedGoogle Scholar
- Hardy J, Vezina JL: Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol. 1976, 15: 261-273.PubMedGoogle Scholar
- Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006, 91: 4769-4775. 10.1210/jc.2006-1668.View ArticlePubMedGoogle Scholar
- Fernandez A, Karavitaki N, Wass JAH: Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010, 72: 377-382. 10.1111/j.1365-2265.2009.03667.x.View ArticleGoogle Scholar
- Colao A, Pivonello R, Di Somma C, Tauchmanovà L, Savastano S, Lombardi G: Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clin Endocrinol (Oxf). 2007, 66: 714-722. 10.1111/j.1365-2265.2007.02809.x.View ArticleGoogle Scholar
- Abe T, Tara LA, Lüdecke DK: Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery. 1999, 45: 1-10. 10.1097/00006123-199907000-00001.View ArticlePubMedGoogle Scholar
- Cannavò S, Venturino M, Curtò L, De Menis E, D'Arrigo C, Tita P, Billeci D, Trimarchi F: Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf). 2003, 58: 519-527. 10.1046/j.1365-2265.2003.01748.x.View ArticleGoogle Scholar
- De Menis E, Visentin A, Billeci D, Tramontin P, Agostini S, Marton E, Conte N: Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J Endocrinol Invest. 2001, 24: 92-97.View ArticlePubMedGoogle Scholar
- Dyer EH, Civit T, Visot A, Delalande O, Derome P: Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery. 1994, 34: 207-212, discussion 212. 10.1227/00006123-199402000-00001.View ArticlePubMedGoogle Scholar
- Kunwar S, Wilson CB: Pediatric pituitary adenomas. J Clin Endocrinol Metab. 1999, 84: 4385-4389. 10.1210/jc.84.12.4385.View ArticlePubMedGoogle Scholar
- Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi CL, Yaneva M, Urban JD, Petrossians P, Elenkova AP, Tabarin A, Desailloud R, Maiter D, Schürmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Fajardo Montañana C, Hana V, Halaby G, Delemer B, Labarta JI, Sonnet E, Ferrandez A, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A: High Prevalence of AIP Gene Mutations Following Focused Screening in Young Patients with Sporadic Pituitary Macroadenomas. Eur J Endocrinol. 2011.Google Scholar
- Pandey P, Ojha BK, Mahapatra AK: Pediatric pituitary adenoma: a series of 42 patients. J Clin Neurosci. 2005, 12: 124-127. 10.1016/j.jocn.2004.10.003.View ArticlePubMedGoogle Scholar
- Katavetin P, Cheunsuchon P, Swearingen B, Hedley-Whyte ET, Misra M, Levitsky LL: Review: Pituitary adenomas in children and adolescents. J Pediatr Endocrinol Metab. 2010, 23: 427-431. 10.1515/jpem.2010.072.PubMedGoogle Scholar
- Georgitsi M, De Menis E, Cannavò S, Mäkinen MJ, Tuppurainen K, Pauletto P, Curtò L, Weil RJ, Paschke R, Zielinski G, Wasik A, Lubinski J, Vahteristo P, Karhu A, Aaltonen LA: Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf). 2008, 69: 621-627. 10.1111/j.1365-2265.2008.03266.x.View ArticleGoogle Scholar
- Cazabat L, Bouligand J, Chanson P: AIP mutation in pituitary adenomas. N Engl J Med. 2011, 364: 1973-1974. author reply 1974-1975.View ArticlePubMedGoogle Scholar
- Stratakis CA, Tichomirowa MA, Boikos S, Azevedo MF, Lodish M, Martari M, Verma S, Daly AF, Raygada M, Keil MF, Papademetriou J, Drori-Herishanu L, Horvath A, Tsang KM, Nesterova M, Franklin S, Vanbellinghen JF, Bours V, Salvatori R, Beckers A: The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in a large cohort of children and adolescents with pituitary adenomas. Clin Genet. 2010, 78: 457-463. 10.1111/j.1399-0004.2010.01406.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Z-gang Mao, Y-hong Zhu, H-liang Tang, D-yuan Wang, Zhou J, D-sheng He, Lan H, B-ning Luo, H-jun Wang: Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol. 2010, 162: 661-666. 10.1530/EJE-09-0908.View ArticleGoogle Scholar
- van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW: Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab. 2001, 86: 478-481. 10.1210/jc.86.2.478.View ArticlePubMedGoogle Scholar
- Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA, Robey PG, Collins MT: Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. J Clin Endocrinol Metab. 2006, 91: 2960-2966. 10.1210/jc.2005-2661.View ArticlePubMedGoogle Scholar
- Galland F, Kamenicky P, Affres H, Reznik Y, Pontvert D, Le Bouc Y, Young J, Chanson P: McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J Clin Endocrinol Metab. 2006, 91: 4957-4961. 10.1210/jc.2006-0561.View ArticlePubMedGoogle Scholar
- Personnier C, Cazabat L, Bertherat J, Gaillard S, Souberbielle JC, Habrand JL, Dufour C, Clauser E, SainteRose C, Polak M: Clinical features and treatment of pediatric somatotropinoma: case study of an aggressive tumor due to a new AIP mutation and extensive literature review. Horm Res Paediatr. 2011, 75 (6): 392-402. 10.1159/000327831.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.